Skip to content

Based on my review and the GO-CAM documentation, I'll now provide a thorough assessment of the GO-CAM model with ID 5ee8120100000524.

Review of GO-CAM Model: 5ee8120100000524 ("SP_N4BP3on MAVS")

Summary of the Model

This GO-CAM model represents a signaling pathway involving N4BP3 (NEDD4 binding protein 3) regulation of MAVS (Mitochondrial antiviral-signaling protein) in the context of innate immune antiviral response. The model includes:

  1. NEDD4 (E3 ubiquitin-protein ligase) with ubiquitin protein ligase activity
  2. N4BP3 with protein binding activity
  3. MAVS with signaling adaptor activity
  4. TRAF2 with ubiquitin protein ligase binding activity

Model Structure and Connections

The model shows a linear pathway where: - N4BP3 directly positively regulates (RO:0002629) NEDD4 - NEDD4 directly positively regulates (RO:0002629) MAVS - MAVS directly positively regulates (RO:0002629) TRAF2

All activities in the model are linked to evidence from the literature, primarily PMID:34880843, with TRAF2's activity also referencing PMID:23951545.

Assessment of Biological Content

The model captures key aspects of the research presented in PMID:34880843, which shows that N4BP3 positively regulates RIG-I-like receptor antiviral signaling by targeting MAVS. According to the paper, N4BP3 promotes the ubiquitination of MAVS, which enhances the interaction between MAVS and TRAF2.

Specifically, the model represents: 1. The interaction between N4BP3 and NEDD4 (N4BP3 is a NEDD4 binding protein) 2. NEDD4's role in ubiquitinating MAVS 3. The enhanced interaction between MAVS and TRAF2

Quality Control Assessment

Strengths of the Model:

  1. Evidence-based: All activities are supported by primary literature references
  2. Appropriate molecular functions: Each protein is annotated with a biologically appropriate molecular function
  3. Logical causal relationships: The causal connections between activities make biological sense
  4. Parsimony: The model focuses on the key proteins and activities in the pathway without unnecessary complexity

Areas for Improvement:

  1. Biological Process context:

  2. The model includes a reference to "innate immune response" (GO:0045087) in the objects list, but this process isn't explicitly connected to any of the activities in the model. According to GO-CAM guidelines, molecular functions should be placed in the context of biological processes.

  3. E3 ligase representation:

  4. Based on the E3 ubiquitin ligase guidelines, the model should indicate that NEDD4's activity "has input" MAVS as its substrate, which is not explicitly shown.

  5. The biological process of ubiquitination (e.g., protein K63-linked ubiquitination) should be included to provide context for NEDD4's activity.

  6. MAVS as a signaling adaptor:

  7. According to the paper, MAVS acts as a signaling adaptor that interacts with TRAF2, but the model doesn't show what MAVS adapts signals to or from.

  8. The paper shows that MAVS is part of the RIG-I-like receptor antiviral signaling pathway, which could be represented more explicitly.

  9. N4BP3's functional role:

  10. While N4BP3 is shown with "protein binding" activity, the paper demonstrates it has a more specific role in promoting ubiquitination of MAVS, which could be better represented.

  11. Missing connection to downstream antiviral response:

  12. The model doesn't represent how this pathway connects to the ultimate outcome of enhanced antiviral response and interferon production, which is a key finding in the paper.

  13. Cellular location context:

  14. The model doesn't include information about the cellular locations of these activities. According to the literature, MAVS is located on the mitochondrial outer membrane, which is crucial for its function.

Specific Recommendations for Improvement

  1. Add Biological Process context:

  2. Connect each activity to the appropriate biological process terms, such as:

    • "innate immune response" (GO:0045087)
    • "antiviral innate immune response" (GO:0140374)
    • "defense response to virus" (GO:0051607)
    • "protein ubiquitination" (GO:0016567) or more specifically "protein K63-linked ubiquitination" (GO:0070534)

  3. Improve E3 ligase annotation:

  4. Add "has input" relation from NEDD4's ubiquitin protein ligase activity to MAVS

  5. Include the biological process of ubiquitination as part of NEDD4's activity context

  6. Clarify MAVS signaling adaptor role:

  7. Show that MAVS adapts signals from RIG-I-like receptors to downstream effectors

  8. Add a "has input" relation for MAVS's signaling adaptor activity

  9. Refine N4BP3 annotation:

  10. Consider annotating N4BP3 with a more specific function, if supported by the evidence

  11. Clearly indicate its role in enhancing MAVS ubiquitination

  12. Add downstream signaling:

  13. Extend the model to show how TRAF2 activation leads to activation of the type I interferon pathway

  14. Include IRF3 activation and/or NF-κB activation, which are key outcomes mentioned in the paper

  15. Add cellular location information:

  16. Include "occurs in" relations to specify the cellular locations of the activities
  17. Particularly important for MAVS (mitochondrial outer membrane)

Conclusion

The GO-CAM model 5ee8120100000524 provides a foundation for representing the N4BP3-MAVS-TRAF2 signaling pathway in antiviral response. It captures key aspects of the pathway but would benefit from additional context and refinement to fully represent the biological insights from the supporting literature. With the recommended improvements, the model would be more comprehensive and aligned with GO-CAM best practices.

The model represents an important innate immune signaling pathway that contributes to our understanding of antiviral responses, particularly how N4BP3 positively regulates MAVS-mediated signaling through promoting MAVS ubiquitination and enhancing its interaction with TRAF2.